GAMMA Investing LLC Purchases 37,735 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

GAMMA Investing LLC increased its holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 4,151.3% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 38,644 shares of the company's stock after acquiring an additional 37,735 shares during the quarter. GAMMA Investing LLC owned about 0.08% of Amphastar Pharmaceuticals worth $1,120,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also added to or reduced their stakes in the stock. Boston Partners purchased a new position in shares of Amphastar Pharmaceuticals during the fourth quarter valued at about $15,778,000. Wealthfront Advisers LLC purchased a new stake in Amphastar Pharmaceuticals in the fourth quarter worth about $9,268,000. Systematic Financial Management LP bought a new stake in Amphastar Pharmaceuticals during the 4th quarter valued at approximately $9,147,000. Dimensional Fund Advisors LP grew its holdings in shares of Amphastar Pharmaceuticals by 9.6% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,198,590 shares of the company's stock worth $44,503,000 after acquiring an additional 105,288 shares during the period. Finally, D. E. Shaw & Co. Inc. grew its holdings in shares of Amphastar Pharmaceuticals by 402.4% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 118,851 shares of the company's stock worth $4,413,000 after acquiring an additional 95,192 shares during the period. Institutional investors own 65.09% of the company's stock.

Amphastar Pharmaceuticals Stock Down 1.1%

AMPH stock traded down $0.27 on Thursday, reaching $25.34. 393,981 shares of the company traded hands, compared to its average volume of 490,302. The firm has a fifty day simple moving average of $24.72 and a 200-day simple moving average of $30.56. The company has a market cap of $1.19 billion, a P/E ratio of 9.18, a price-to-earnings-growth ratio of 6.67 and a beta of 0.77. Amphastar Pharmaceuticals, Inc. has a one year low of $22.64 and a one year high of $53.96. The company has a debt-to-equity ratio of 0.80, a current ratio of 2.95 and a quick ratio of 2.02.

Analyst Upgrades and Downgrades

AMPH has been the subject of a number of research analyst reports. Wells Fargo & Company lowered their target price on Amphastar Pharmaceuticals from $40.00 to $35.00 and set an "overweight" rating for the company in a research note on Thursday, May 8th. Piper Sandler lowered their price objective on Amphastar Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating for the company in a research report on Friday, March 21st. Needham & Company LLC restated a "hold" rating on shares of Amphastar Pharmaceuticals in a report on Thursday, April 10th. Finally, JPMorgan Chase & Co. reiterated a "neutral" rating and issued a $30.00 price target (down from $45.00) on shares of Amphastar Pharmaceuticals in a research note on Monday, May 12th. Four investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat, Amphastar Pharmaceuticals presently has a consensus rating of "Hold" and a consensus price target of $32.33.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.